CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

Nature Medicine

Volumn 5, Issue 7, 1999, Pages 774-779

  Diehl, Linda ^d   Den Boer, Annemieke Th ^d   Schoenberger, Stephen P ^a   Van Der Voort, Ellen I H ^d   Schumacher, Ton N M ^b   Melief, Cornelis J M ^d   Offringa, Rienk ^d   Toes, Rene E M ^c  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; DRUG EFFICACY; HELPER CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CANCER VACCINES; CD40 LIGAND; CELL TRANSFORMATION, NEOPLASTIC; EPITOPES; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

ANIMALIA;

EID: 0032984496     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/10495     Document Type: Article

References (32)

1. Aichele, P., Brduscha-Riem, K., Zinkernagel, R.M., Hengartner, H. & Pircher, H. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182, 261-266 (1995).
2. Feltkamp, M.C. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993).
3. Aichele, P. et al. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 91, 444-448 (1994).
4. Aichele, P. et al. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6, 519-529 (1997).
5. Toes, R.E., Blom, R.J., Offringa, R., Kast, W.M. & Melief, C.J. Enhanced tumor out-growth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918 (1996).
6. Toes, R.E.M., Offringa, R., Blom, R.J.J., Melief, C.J.M. & Kast, W.M. Peptide vaccination can lead to enhanced tumor growth through specific T cell tolerance induction. Proc. Natl. Acad. Sci. USA 93, 7855-7860 (1996).
7. Toes, R.E. et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160, 4449-4456 (1998).
8. Guerder, S. & Matzinger, P. A fail-safe mechanism for maintaining self-tolerance. J. Exp. Med. 176, 553-564 (1992).
9. Kurts, C. et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186, 2057-2062 (1997).
10. Schoenberger, S.P., Toes, R.E.M., Vandervoort, E.I.H., Offringa, R. & Melief, C.J.M. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40I interactions. Nature 393, 480-483 (1998).
11. Bennett, S.R.M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393, 478-480 (1998).
12. Cella, M. et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-752 (1996).
13. Ridge, J.P., Dirosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4(+) T-helper and a T-killer cell. Nature 393, 474-478 (1998).
14. Ding, L. & Shevach, E.M. Activated B cells express CD28/B7-independent costimulatory activity. J. Immunol. 157, 1389-1396 (1996).
15. Bennett, S.R., Carbone, F.R., Toy, T., Miller, J.F. & Heath, W.R. B cells directly tolerize CD8(+) T cells. J. Exp. Med. 188, 1977-1983 (1998).
16. Feltkamp, M.C. et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-in-duced tumors. Eur. J. Immunol. 25, 2638-2642 (1995).
17. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302 (1995).
18. Parker, D.C. et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92, 9560-9564 (1995).
19. Yang, Y. et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70, 6370-6377 (1996).
20. Rees, M.A., Rosenberg, A.S., Munitz, T.I. & Singer, A. In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help. Proc. Natl. Acad. Sci. USA 87, 2765-2769 (1990).
21. Anderton, S.M., van der Zee, R. & Goodacre, J.A. Inflammation activates self hsp60-specific T cells. Eur. J. Immunol. 23, 33-38 (1993).
22. Howell, C.D. & Yoder, T.D. Murine experimental autoimmune hepatitis: nonspecific inflammation due to adjuvant oil. Clin. Immunol. Immunopothol. 72, 76-82 (1994).
23. Fayolle, C. et al. Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology 89, 41-45 (1996).
24. Ehl, S. et al. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J. Exp. Med. 187, 763-774 (1998).
25. Dullforce, P., Sutton, D.C. & Heath, A.W. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nature Med. 4, 88-91 (1998).
26. Kawabe, T. et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1, 167-178 (1994).
27. Rolink, A., Melchers, F. & Andersson, J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5, 319-330 (1996).
28. Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350, 423-426 (1991).
29. Schoenberger, S.P. et al. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res. 58, 3094-3100 (1998).
30. Lin, K.Y. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26 (1996).
31. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
32. Haanen, J.B. et al. Systemic T cell expansion during localized viral infection. Eur. J. Immunol. 29, 1168-1174 (1999).